



Press Release

Claris Lifesciences announces settlement of litigations and license agreement for its generic DIPRIVAN in USA.

Ahmedabad, India, 20th April 2015: Claris Lifesciences Limited (Claris) confirms that it has reached a settlement and license agreement, ending all pending litigation with Fresenius Kabi USA, Inc. with reference to the alleged infringement of a patent relating to Propofol for Injection, 10 mg/ml, which is a generic version of DIPRIVAN.

Under the terms of the Settlement and License Agreement, Claris and Claris Lifesciences Inc. (USA) has been granted approval to sell its generic version of Propofol for Injection beginning 15th October 2016, prior to the 1st June 2025 expiry of the patent that formed the basis of the litigation.

According to IMS health data as of June 2014, Propofol Injection had an annual market size of approximately US\$ 251 million in the USA.

###

Disclaimer

This press release may include "forward-looking statements" which involve a number of risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future. Claris Lifesciences Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Market information mentioned in the press release is based on IMS Data and/or internal estimates of the company.

About Claris Lifesciences Limited

Claris Lifesciences Limited (BSE Code: 533288) is the holding company with three segmental revenues (i) the Speciality Injectables Business which is housed in a wholly owned subsidiary; Claris Injectables Limited, (ii) 20% stake in the Joint Venture with Otsuka and Mitsui for the Infusion Business in India and Emerging Markets, and (iii) the Treasury and Cash management for the funds in the Hold Co.

For more information about the company, log on to: www.clarislifesciences.com

About Claris Lifesciences Inc.

Claris Lifesciences Inc. is a pure play injectables company, involved in marketing and distribution of generic injectables in United States. The company is a wholly-owned subsidiary of Claris Lifesciences Ltd. Headquartered in New Jersey, USA, Claris Inc. has full-fledged presence to cater to the growing and unmet demands of hospitals and medical professionals for injectable products. Claris Inc. has full-fledged sales, marketing and regulatory capabilities established to ensure seamless product availability and after-sales services and to ensure customer delight at every step of value chain.

Claris Lifesciences Limited

Claris Corporate Headquarters, Nr. Parimal Rly. Crossing,
Ellisbridge, Ahmedabad 380 006, India.
Tel: +91-79-26563331, 66309339 Fax: +91-79-26408053
www.clarislifesciences.com

(Corporate Identity Number: L85110GJ1994PLC022543)



Claris

With 13 ANDAs across 8 molecules and a growing portfolio, Claris Inc. is one of a few players to have launched technologically-advanced and complex-to-manufacture products in premix bags both PVC and non-PVC materials. The other technological platforms include glass vials and ampoules. Having established a strong team to address customer needs personally and provide prompt & satisfactory services, the company places major emphasis on quality and technology of products, which are manufactured at cGMP compliant facilities inspected by FDA.

For more information about the company, log on to: <http://www.us.clarislifesciences.com>

About Propofol

Propofol is a complex product to manufacturing with very few company manufacturing this product, this results into the product facing shortages sometimes. Propofol is a product of choice for anaesthetics' and it has been growing faster than the anaesthesia market. The company has capacities to manufacture 50+ mn units per year, which accounts to an estimated 25% of the market size of Regulated Markets. With over 10 years of experience in manufacturing Propofol and sales in over 50 countries, this product is one of the flagship products for the company. Claris; as compared to its competitors; is well positions to acquire a sizable market share in the US and other regulated markets as it is the only company to have an India cost advantage and economies of scale.

For more information about the product, log on to: <http://www.clarisinj.com/Claris-Injectables-Propofol-Prosafe.html>

Claris Lifesciences Limited

Claris Corporate Headquarters, Nr. Parimal Rly. Crossing,
Ellisbridge, Ahmedabad 380 006, India.
Tel: +91-79-26563331, 66309339 Fax: +91-79-26408053
www.clarislifesciences.com

(Corporate Identity Number: L85110GJ1994PLC022543)